Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Yi Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Aesthetics, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, Chi…. Hauptthemen laut MEDLINE: Melanoma, GTP Phosphohydrolases, Membrane Proteins, Skin Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Mutant NRAS is the second-most common type of mutation in melanoma. The prognosis in patients with NRAS mutant melanoma is poor, and effective targeted treatment strategies are still lacking. Mutant NRAS mainly acts by activating RAF–MEK–ERK signalling to promote carcinogenesis in melanoma. In recent years, significant clinical advances have been made in targeting the NRAS–MAPK (mitogen-activated protein kinase) pathway, with novel therapies such as the MEK inhibitor tunlametinib and a combination therapy of the pan-RAF inhibitor naporafenib + trametinib leading the way. In this review, we systematically summarize the recent advances made in the direct targeting of mutant NRAS proteins and their downstream RAF and MEK proteins, as well as targeting the MAPK pathway in combination with other therapeutic targets, including immunotherapy, to treat NRAS mutant melanoma. Additionally, we discuss the current issues and emerging countermeasures related to targeted therapy for NRAS mutant melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Aesthetics, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
- Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
- The Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine, Zunyi Medical University, Zunyi, Guizhou, China.
- Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Guangchao Xu, Hongwei Xia
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Science and Technology Department of Sichuan Province
Zitieren
APA
Wang, Y., Xu, G., & Xia, H. (2025). Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf178
Vancouver
Wang Y, Xu G, Xia H. Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf178
BibTeX
@article{Wang2025,
author = {Wang, Yi and Xu, Guangchao and Xia, Hongwei},
title = {Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf178}
}
EUVIMED